Compare ERO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | NAMS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Canada | Netherlands |
| Employees | N/A | 100 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2021 | N/A |
| Metric | ERO | NAMS |
|---|---|---|
| Price | $25.42 | $28.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $36.50 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 936.7K | 838.8K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.94 | $17.96 |
| Revenue Next Year | $2.43 | $540.65 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $16.79 |
| 52 Week High | $39.80 | $42.00 |
| Indicator | ERO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 36.54 |
| Support Level | $23.01 | $23.48 |
| Resistance Level | $26.77 | $37.25 |
| Average True Range (ATR) | 1.21 | 1.69 |
| MACD | -0.37 | -0.61 |
| Stochastic Oscillator | 1.94 | 7.66 |
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.